氟西汀与阿米替林治疗105例抑郁障碍病人的双盲对照试验

目的：评价国产氟西汀的抗抑郁作用及安全性。方法：采用随机、双盲对照、多中心研究，分为国产氟西汀组５７例（男性２２例，女性３５例；年龄４０±ｓ１３ａ），口服氟西汀２０ｍｇ，ｑｄ，阿米替林５７例（男性２７例，女性３０例；年龄４０±１４ａ），口服阿米替林７５ｍｇ，ｂｉｄ，疗程６ｗｋ。结果：氟西汀治疗抑郁障碍的疗效与阿米替林相当，总有效率分别为８５％及９２％（Ｐ＞０．０５）；氟西汀组的主要副作用有口干、便秘、恶心、心动过速等，但较之阿米替林程度轻且发生率低。结论：氟西汀的抗抑郁作用与阿米替林相当，副作用少，服用方便。     

初治鼻咽癌调强放疗的初步结果

目的分析调强放疗（IMRT）在初治鼻咽癌应用的初步结果.方法76例经病理证实的初治鼻咽癌患者接受了全程IMRT.根据1992年福州分期标准,Ⅰ期2例,Ⅱ期20例,Ⅲ期29例,Ⅳ期25例.采用多叶光栅的静态调强技术实施IMRT,采用的逆向治疗计划系统分别为TMS、CMS和Pinnacle.各靶区处方剂量均以其PTV定义给予,鼻咽肿瘤（GTV）和颈部淋巴结（GTV-LN）处方剂量为68～76Gy,鼻咽区域及上颈部临床靶区（CTV1）处方剂量为58～66Gy.下颈部锁骨上区域（CTV2）37例采用IMRT技术,处方剂量为50～60Gy,39例采用常规技术单前切线野照射.晶体、脑干、脊髓、视神经和视交叉的最高限量（99%体积低于此剂量）分别为8、54、40、54、54 Gy.7例合并同时化疗,4例IMRT后鼻咽局部予以立体定向放疗加量.采用Kaplan-Meier法计算生存率,RTOG标准评价急性副反应.结果中位随访期为10个月,全组死亡3例,分别死于鼻咽肿瘤未控大出血、肝转移和治疗相关并发症.1、2年总生存率分别为92%、92%;鼻咽和颈部1、2年局部控制率均为95%,4例出现了远处转移;1、2年无瘤生存率分别为95%、86%.急性反应以1、2级为主,其中唾液腺为99%,咽部和黏膜分别为88%和72%.GTV、GTV-LN、CTV1、CTV2的平均剂量均值分别为74.3、74.1、67.2、60.2Gy,平均低于95%处方剂量的靶区体积分别为0.58%、0.31%、0.67%、0.59%.左、右腮腺的中位剂量分别为33.9、34.0 Gy,晶体、脑干、脊髓、视神经、交叉最高剂量平均值分别为7.2、53.4、41.6、53.4、55.6 Gy.结论调强放疗技术能对初治鼻咽癌的各靶区达到很好的剂量分布,达到较高局部控制率,并降低了周围危及器官剂量和急性治疗反应,远期结果需进一步观察.     

绵阳市2014年MSM艾滋病知识和行为特征及性行为保护性影响因素

目的 了解男男性行为人群(MSM)艾滋病知识及行为现状,分析性行为保护性影响因素。 方法 2014年4-10月,以绵阳市辖区所辖9个县(市、区)MSM为对象,在固定场所知情同意下,应用滚雪球抽样法,进行调查对象招募和自填式匿名行为学调查和血清学检测。采用χ²检验比较率,采用非条件logistic回归分析探讨MSM性行为保护性影响因素。 结果 共调查1 097例,艾滋病知识知晓率99.0%(1 086/1 097),近6月男性肛交85.6%(939/1 097)、商业性行为1.7%(16/939)、异性性行为8.2%(90/1 097),近6月性行为保护性分别依次为68.7%(640/932)、37.5%(6/16)、24.4%(22/90),近1次分别依次为89.3%(832/932)、62.5%(10/16)、61.1%(55/90),不同地区男性肛交、异性性行为保护性差异有统计学意义(均P＜0.05)。近6月男性肛交有、无保护性艾滋病病毒(HIV)感染率分别为1.6%(10/640)、8.6%(25/292)(P=0.000)。多因素分析结果:文化程度高中/中专(OR=1.621,95%CI: 1.028～2.555,P=0.038),本地居住时间≥3个月(OR=8.353,95%CI:1.666～41.878,P=0.010)、知晓艾滋病知识(OR=1.774,95%CI: 1.064～2.960,P=0.028)、近1年接受过预防服务(OR=3.690,95%CI: 2.591～5.236,P=0.000)是MSM有保护性行为的促进因素,近1周肛交次数≥2(OR=0.516,95%CI:0.363～0.733,P=0.000)是危险因素。 结论 2014年绵阳市MSM艾滋病知识知晓率高,性行为保护性地区间不平衡,整体水平不高,受文化程度、本地居住时间、艾滋病知识知晓、预防服务、肛交频率等影响,应针对性开展行为干预。     

龙胆泻肝汤联合西药治疗带状疱疹随机平行对照研究

[目的]观察龙胆泻肝汤联合西药治疗带状疱疹疗效。[方法]使用随机平行对照方法,将30例门诊患者按就诊顺序编号方法随机分为两组,治疗期间均禁食辛辣及油腻食物,戒烟、酒。对照组15例阿昔洛韦0．2g／次,1次／8h;三氮唑核苷（病毒唑）10mg／kg＋5％萄糖500mL静滴,1次／d;甲钴胺250～500ug,1次／d。伴水泡破裂2．5％龙胆紫溶液涂患处。治疗组15例龙胆泻肝汤（龙胆草10g,连翘、生地各15g,泽泻lOg,木通8g,车前子、黄芩、生栀仁、丹皮各10g,板蓝根、牛蒡子各15g,佩兰、甘草各lOg）,水2000mL煎至500mL,3～4次／d,温服。疼痛重外用京墨涂抹。西药治疗同对照组。连续治疗7d为1疗程,治疗3个疗程。观测临床症状,皮疹、止疱、止痛、结痂、皮损痊愈时间,不良反应。治疗1疗程,判定疗效。[结果]治疗组痊愈12例,显效3例,总有效率100．00％。对照组痊愈6例,显效3例,无效6例,总有效率60．00％。治疗组疗效优于对照纽（P〈0．05）。止痛、止疱、结痂时间,总病程治疗纽均显著短于对照纽（P〈0．05）。[结论]龙胆泻肝汤联合西药治疗带状瑭．疮．疗效满意齐．副作用．佶彳导旌产．     

Improving outcomes in the treatment of locally-advanced NSCLC with gemcitabine

Multiple approaches of combined modality therapy have emerged as potential treatments for improving unresectable, locoregionally advanced non-small-cell lung cancer (NSCLC). Several agents have been used either sequentially or concurrently in clinical trials of combined chemoradiotherapy. However, no specific regimen has been clearly defined, particularly with regard to the timing of chemotherapy (sequential and/or concurrent), the specific chemotherapeutic drugs, and the dose and intensity of the radiation therapy. Concurrent chemoradiotherapy demonstrates a survival advantage compared to sequential chemoradiotherapy. Initial data suggest that induction chemotherapy prior to concurrent chemoradiotherapy does not further improve survival. The potent radiosensitizer gemcitabine has been evaluated in combination chemotherapy with radiation therapy and appears to be a promising agent, although further trials are needed to define its optimal dose, toxicity and efficacy.     

莫沙必利治疗功能性消化不良多中心双盲对照研究

目的 :观察莫沙必利治疗功能性消化不良的有效性及安全性。方法 :采用双盲随机对照研究 ,2 55名功能性消化不良病人。随机分为 2组 :莫沙必利组 12 7例 (男性 58例 ,女性 6 9例 ,年龄 4 0a±s 12a)用莫沙必利 5mg ,po ,tid ;多潘立酮组 12 8例(男性 6 1例 ,女性 6 7例 ;年龄 39a± 12a)用多潘立酮 10mg ,po ,tid。疗程均为 4wk。结果 :莫沙必利治疗 4wk ,上腹疼痛、上腹饱胀、嗳气、进食减少及早饱等症状的总有效率分别为 77.8% ,86 .6 % ,82 .5% ,87.3% ,87.2 %。明显高于多潘立酮的6 3.5% ,75.0 % ,6 9.6 % ,74 .1% ,74 .5%。莫沙必利组治疗后胃半排空时间缩短 15min± 13min ,明显高于多潘立酮组 5min± 16min。结论 :莫沙必利是一种新型安全有效的治疗功能性消化不良的药物。     

白杨黄素影响两种胃癌细胞系增殖与凋亡的研究

 目的 研究白杨黄素对两种胃癌细胞系SGC-7901和MKN-45是否具有抑制作用的分子生物学机制.方法 通过MTT法检测白杨黄素对SGC-7901和MKN-45细胞的增殖抑制作用,流式细胞术测定经白杨黄素处理后两种细胞的细胞周期,Westen-blot测定凋亡相关因子Caspase-3、Survivin和Bcl-2的表达水平.结果 白杨黄素对SGC-7901和MKN-45细胞具有增殖抑制作用,呈时间浓度依赖性;能够将细胞周期阻滞于Sub G1期;能上调Caspase-3,下调Survivin和Bcl-2的基因表达.结论 白杨黄素能够诱导SGC-7901和MKN-45细胞的凋亡并有效地抑制其增殖.其机制可能与干扰细胞周期及激活Caspase-3,抑制Survivin和Bcl-2有关.     

HIV-associated lipodystrophy

The HIV associated lipodystrophy syndrome is characterized by fat loss from the periphery, fat accumulation in the abdominal, dorsocervical regions and breasts, and hyperlipidaemia, insulin resistance and lactic acidaemia. Although several mechanisms have been proposed to explain these abnormalities, the exact aetiology of the condition remains unclear and will likely prove to be complex. The principal clinical concerns that arise from this disorder are possible increased risks of premature atherosclerosis and cardiovascular disease. A variety of therapeutic interventions, designed to limit these risks, are under evaluation.     

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial.

PURPOSE: Although several new chemotherapeutic agents are promising as primary therapy in non-small-cell lung cancer (NSCLC), few have demonstrated activity in platinum-refractory disease. Based on encouraging results reported in two single-institution studies of docetaxel in this setting, we performed a multicenter phase II trial evaluating this novel taxane in previously treated NSCLC patients prospectively categorized by platinum response status. PATIENTS AND METHODS: Eighty patients with NSCLC previously treated with platinum-based chemotherapy received docetaxel at a dose of 100 mg/m(2) intravenously over 1 hour, repeated every 21 days, accompanied by dexamethasone 8 mg orally twice daily for 5 days. Forty-seven patients (59%) were defined as platinum-refractory based on response status to prior therapy. RESULTS: The median number of cycles delivered per patient was four (range, one to 21 cycles). Partial response was observed in 13 (16%) of 80 of patients, with similar response rates in platinum-sensitive and platinum-refractory patients. The median survival time was 7 months, and the 1-year survival rate was 25%. Docetaxel was relatively well tolerated in this previously treated population. Grade IV neutropenia was common in patients (77%) but typically of brief duration. Febrile neutropenia was observed in 11 patients (14%), with no fatal infections. Severe fluid retention was rare (4% of patients). CONCLUSIONS: This multicenter phase II trial confirms antitumor activity and encouraging survival with docetaxel therapy in platinum-treated and platinum-refractory NSCLC. To validate these results, a phase III trial randomizing platinum-treated patients to docetaxel or best supportive care is underway.